From: Locoregional therapy in luminal-like and HER2-enriched patients with de novo stage IV breast cancer
Univariate | Multivariate | |||||
---|---|---|---|---|---|---|
Variable | HR | 95%CI | P | HR | 95% CI | P |
Luminal-like | 1 | 1 | ||||
HER2–enriched | 2.0 | 1.4-2.8 | < 0.0001 | 2.2 | 1.5-3.1 | < 0.0001 |
Triple negative | 4.2 | 2.8-6.2 | < 0.0001 | 4.3 | 2.9-6.5 | < 0.0001 |
cT1-3 vs. cT4 | 0.7 | 0.5-0.9 | 0.011 | |||
NG 1–2 vs. NG 3 | 0.9 | 0.5-1.4 | 0.5386 | |||
LVI | ||||||
focal vs. no | 0.6 | 0.3-1.4 | 0.2649 | |||
Prominent vs. no | 0.5 | 0.3-1.0 | 0.0616 | |||
Lymph node involvement | 1.1 | 0.8-1.5 | 0.6471 | |||
CEA elevated vs. normal | 1.1 | 0.8-1.5 | 0.3969 | |||
CA 153 elevated vs. normal | 1.1 | 0.8-1.4 | 0.6379 | |||
Metastasis | ||||||
Liver, yes vs. no | 2.3 | 1.7-3.2 | < 0.0001 | 1.9 | 1.4-2.5 | 0.0001 |
Lung, yes vs. no | 1.7 | 1.3-2.2 | 0.0004 | 1.4 | 1.1-1.9 | 0.0153 |
Brain, yes vs. no | 1.5 | 1.1-2.3 | 0.0256 | 1.3 | 0.9-1.9 | 0.1728 |
Bone, yes vs. no | 1.3 | 0.9-1.8 | 0.1016 | 1.8 | 1.3-2.5 | 0.0007 |
*Local treatment, yes vs. no | 0.5 | 0.4-0.6 | < 0.0001 | 0.6 | 0.4-0.8 | 0.0008 |